Global R&D Pipeline
My Favorite
Hot Targets:
IL4
Back
Total number of drugs
30
Phase II and later clinical stages
6.7%
Involving companies
29
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-IL-4/IL-13 antibody (Beijing VDJBio) | Anti-IL-4/IL-13 antibody (Beijing VDJBio) | Bispecific antibody | Other Diseases | IL-13 inhibitors IL-4 inhibitors | Beijing Weidejie Biotechnology Co., Ltd. | - | Pending (in Preclinical) | Pending (in Preclinical) | - | - | - | - | - | - | - | - | Anti-IL-4/IL-13 antibody (Beijing VDJBio) | - | - | detail > | |
| ILCT 1001 | ILCT 1001 | Synthetic peptide | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-13 inhibitors IL-17 inhibitors IL-4 inhibitors IL-5 inhibitors | ILC Therapeutics Ltd. | - | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | - | ILCT 1001 | - | - | detail > | |
| P-45 | P-45 | Small molecule drug | Skin and Musculoskeletal Diseases | IL-4 inhibitors | Ixico Plc | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | P-45 | - | - | detail > | |
| IL-4 gene therapy (University of Pittsburgh) | IL-4 gene therapy (University of Pittsburgh) | Gene therapy | Neoplasms Skin and Musculoskeletal Diseases Urogenital Diseases | IL-4 modulators | University of Pittsburgh | - | Pending (in Phase 1) | - | - | - | - | - | - | - | - | - | IL-4 gene therapy (University of Pittsburgh) | - | - | detail > | |
| HSV-IL-4 | HSV-IL-4 | Virotherapy | Infectious Diseases Eye Diseases | IL-4 stimulants | Cedars-Sinai Medical Center | - | Pending (in Preclinical) | - | - | - | - | - | - | - | - | - | HSV-IL-4 | - | - | detail > | |
| Dectrekumab/VAK-694 | Dectrekumab/VAK-694 | Monoclonal antibody | Immune System Diseases Respiratory Diseases | IL-13 inhibitors IL-4 inhibitors | Novartis Pharma AG | - | Pending (in Phase 2) | - | - | - | - | - | - | - | - | - | Dectrekumab/VAK-694 | - | - | detail > | |
| APG-232 | APG-232 | Monoclonal antibody | Neoplasms | IL-4 modulators | Apogenix AG | - | Pending (in Discovery) | - | - | - | - | - | - | - | - | - | APG-232 | - | - | detail > | |
| VAK-694 | VAK-694 | Monoclonal antibody | Immune System Diseases Infectious Diseases Otorhinolaryngologic Diseases Respiratory Diseases | IL-4 inhibitors | Novartis Pharma AG | - | Pending (in Phase 2) | - | - | - | - | - | - | - | - | - | VAK-694 | - | - | detail > | |
| Interleukin-4/13 Trap | Interleukin-4/13 Trap | Interleukins | Immune System Diseases Respiratory Diseases | IL-13 inhibitors IL-4 inhibitors | Regeneron Pharmaceuticals, Inc. | - | Pending (in Phase 1) | - | - | - | - | - | - | - | - | - | Interleukin-4/13 Trap | - | - | detail > | |
| OCH-NCNP1 | OCH-NCNP1 | Small molecule drug | Immune System Diseases Nervous System Diseases Other Diseases Digestive System Disorders | IFNγ inhibitors IL-4 inhibitors | Keio University | - | Pending (in Phase 2) | - | - | - | - | - | - | - | - | - | OCH-NCNP1 | - | - | detail > |
Total 30 data
1
2
3
